Predictive Response Biomarkers for BET Inhibitors in AML

BET-inhibitors as sensitizers for BH3-mimetics

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma

This corrects the article DOI: 10.1038/cddis.2017.383.

Biomarkers predictive of GSI response in solid tumors

Merck Research Laboratory, Boston MA 02115. Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115. Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadephia, PA 19104. Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02114. Department of Medicine and Digestive Health R...

Predictive response biomarkers in rectal cancer neoadjuvant treatment.

Locally advanced rectal cancer (RC) treatment is a challenge, because RC has a high rate of local recurrence. To date preoperative chemoradiotherapy (pCRT) is widely accepted as standard protocol of care for middle-low RC, but complete tumour response rate ranges from 4 to 44% and 5-year local recurrence rate is 6%. Better understanding of molecular biology and carcinogenesis pathways could be ...

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours.

Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in differ...